Kolonn to introduce Chiesi's respiratory medicines

Published: 2007-05-18 06:56:00

Updated: 2007-05-18 06:56:00

Kolon Pharm and Chiesi Farmaceutici S.p.A. in Italy has recently signed a distirbution agreement to release Chiesi's five respiratory drugs including Foster Formoterol Modulite, an HFA-based pressurised metered-dose inhaler (pMDI) product, in Korea.

Under the agreement, Kolon will have promoti...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK